2-(4-氟苯甲基磺酰)羟基乙脒 | 175276-85-4

• 物质功能分类: 化学试剂 - 有机试剂 - 亚氨、脒
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氟苯甲基磺酰)羟基乙脒
• 英文名称: 2-[(4-fluorobenzyl)sulfonyl]-N-hydroxyethanimidamide
• 英文别名: 2-(4-Fluorobenzylsulfonyl)Acetamidoxime；2-[(4-fluorophenyl)methylsulfonyl]-N'-hydroxyethanimidamide
• CAS: 175276-85-4
• 化学式: C₉H₁₁FN₂O₃S
• mdl: MFCD00052932
• 分子量: 246.262
• InChiKey: AVDGZDWBPJLTHN-UHFFFAOYSA-N

物化性质

• 熔点：
  182 °C
• 沸点：
  474.3±55.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi,T
• 安全说明：
  S45
• 危险类别码：
  R25

反应信息

• 作为反应物：
  描述：

  2-(4-氟苯甲基磺酰)羟基乙脒 在 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 [[1-Amino-2-[(4-fluorophenyl)methylsulfonyl]ethylidene]amino] 5-(2,2,2-trifluoroacetyl)thiophene-2-carboxylate
  参考文献：
  名称：

  WO2007/93827

  摘要：

  公开号：

文献信息

• 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors
  作者：Ester Muraglia、Sergio Altamura、Danila Branca、Ottavia Cecchetti、Federica Ferrigno、Maria Vittoria Orsale、Maria Cecilia Palumbi、Michael Rowley、Rita Scarpelli、Christian Steinkühler、Philip Jones

  DOI：10.1016/j.bmcl.2008.09.076

  日期：2008.12

  class II HDAC inhibitors, with moderate selectivity. Exploration of replacements for the carboxamide with bioisosteric pentatomic heteroaromatic like 1,3,4-oxadiazoles, 1,2,4-oxadiazoles and 1,3-thiazoles, led to the discovery that 2-trifluoroacetylthiophene 1,3,4-oxadiazole derivatives are very potent low nanomolar HDAC4 inhibitors, highly selective over class I HDACs (HDAC 1 and 3), and moderately

  最近已经报道三氟乙酰基噻吩羧酰胺是II类HDAC抑制剂，具有中等选择性。探索用生物等位五原子杂芳族化合物（如1,3,4-恶二唑，1,2,4-恶二唑和1,3-噻唑）替代羧酰胺，导致发现2-三氟乙酰基噻吩1,3,4-恶二唑衍生物是非常有效的低纳摩尔HDAC4抑制剂，对I类HDAC（HDAC 1和3）具有高度选择性，并且在HCT116细胞培养中具有中等稳定性。
• Thiophene and Thiazole Substituted Trifluoroethanone Derivatives as Histone Deacetylase (HDAC) Inhibitors
  申请人：Ferrigno Federica

  公开号：US20090076101A1

  公开（公告）日：2009-03-19

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.

  本发明涉及式(I)的化合物，以及其药学上可接受的盐和互变异构体。本发明的化合物是组蛋白去乙酰化酶（HDAC）的抑制剂，可用于治疗细胞增殖性疾病，包括癌症。它们还可用于治疗神经退行性疾病、智力低下、精神分裂症、炎症性疾病、再狭窄、免疫系统疾病、糖尿病、心血管疾病和哮喘。
• Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors
  申请人：Istituto di Ricerche di Biologia Molecolare P. Angeletti SpA

  公开号：US07799825B2

  公开（公告）日：2010-09-21

  The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts and tautomers thereof. Compounds of the present invention are inhibitors of histone deacetylase (HDAC) and are useful for treating cellular proliferative diseases, including cancer. They are also useful for treating neurodegenerative diseases, mental retardation, 10 schizophrenia, inflammatory diseases, restenosis, immune disorders, diabetes, cardiovascular disorders and asthma.

  本发明涉及式（I）的化合物以及其药学上可接受的盐和互变异构体。本发明的化合物是组蛋白去乙酰化酶（HDAC）的抑制剂，可用于治疗细胞增殖性疾病，包括癌症。它们还可用于治疗神经退行性疾病、智力低下、精神分裂症、炎症性疾病、再狭窄、免疫紊乱、糖尿病、心血管疾病和哮喘。
• Identification of Novel, Selective, and Stable Inhibitors of Class II Histone Deacetylases. Validation Studies of the Inhibition of the Enzymatic Activity of HDAC4 by Small Molecules as a Novel Approach for Cancer Therapy
  作者：Jesus M. Ontoria、Sergio Altamura、Annalise Di Marco、Federica Ferrigno、Ralph Laufer、Ester Muraglia、Maria Cecilia Palumbi、Michael Rowley、Rita Scarpelli、Carsten Schultz-Fademrecht、Sergio Serafini、Christian Steinkühler、Philip Jones

  DOI：10.1021/jm900555u

  日期：2009.11.12

  5-Aryl-2-(trifluoroacetyl)thiophenes were identified as a new series of class II HDAC inhibitors (HDACi). Further development of this new series led to compounds such as 6h, a potent inhibitor of HDAC4 and HDAC6 (HDAC4 WT IC50 = 310 nM, HDAC6 IC50 = 70 nM) that displays 40-fold selectivity over HDAC1 and improved stability in HCT116 cancer cells (t(1/2)= 11 h). Compounds 6h and 2 show inhibition of alpha-tubulin deacetylation in HCT116 cells at 1 mu M concentration and antiproliferation effects only at concentrations where inhibition of historic H3 deacetylation is observed.
• THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS
  申请人：Istituto di Ricerche di Biologia Molecolare P. Angeletti

  公开号：EP1987024A1

  公开（公告）日：2008-11-05